血清甲状腺过氧化物酶抗体联合甲状腺球蛋白抗体检测在碘剂(^(131)I)治疗甲亢患者中的疗效评价作用  

Evaluation of the effects of detection of serum thyroid peroxidase antibody and thyroid globulin antibody in Graves patients with hyperthyroidism treated with ^(131)I

作　　者：陈碧玲[1] 

机构地区：[1]湖北民族学院附属民大医院核医学科,湖北恩施445000

出　　处：《中国医院药学杂志》2013年第22期1865-1867,共3页Chinese Journal of Hospital Pharmacy

摘　　要：目的:探讨甲状腺过氧化物酶抗体(TPOAb)与甲状腺球蛋白抗体(TGAb)在131I治疗Graves病疗效中评价作用,为临床治疗提供参考。方法:采用电化学发光免疫分析法测定147例GD患者中TPOAb、TGAb水平,并根据检测结果分为阳性组和阴性组。分析GD患者与正常人群以及131I治疗GD前后中TPOAb、TGAb水平差异;观察血清TPOAb、TGAb水平动态变化及与甲减的关系。结果:Graves患者血清TPOAb、TGAb水平明显高于对照组(t=6.326,4.260,P<0.05);GD患者血清TPOAb、TGAb水平较治疗前显著降低(t=2.043,2.075,P<0.05)。治疗后3个月、18个月GD患者血清TPOAb阳性率较治疗前显著下降(P<0.05);治疗后6个月血清TGAb阳性率最高,与治疗前相比有统计学差异(P<0.05),18个月后血清TGAb阳性率下降最低,与治疗前相比P<0.05。结论:131I是治疗GD的主要方法,其治疗作用可能与下调血清TPOAb、TGAb水平有关,可以将检测血清TPOAb、TGAb水平作为疗效评价的指标之一。OBJECTIVE To explore the effect of detected TPOAb and TGAb in evaluating the effect of ^131I treatment of Graves disease（GD）, to provide the reference for the clinical treatment. METHODS By using electrochemical chemiluminescence irnmunoassay method, the level of TGAb and TPOAb was determined in 147 cases of GD patients, and aecoMing to the re suits of detection they were divided into positive group and negative group. Analysis of difference in TPOAb,TGAb levels was made between the GD patients and normal persons before and after ^131I treatment; the dynamic change of serum TPOAb, TGAb level with relation to hypothyroidism was observed. RESULTS In Graves patients the levels of serum TPOAb,TGAb were significantly higher than those in the control group （t = 6. 326,4. 260, P〈0.05） ; serum TPOAb, TGAb levels of GD patients were significantly lower after treatment than before （t = 2. 043,2.075, P〈0.05）. 3 months, 18 months after treatment, the positive rate of serum TPOAb was obviously decreased （P〈0.05） ; 6 months after treatment the positive rate of serum TGAh was the highest, there was significant difference compared with before treatment （P〈0. 05）, after 18 months the positive rate of serum TGAb descended to the lowest,compared with before treatment （P〈0. 05）. CONCLUSION ^138I is the main treatment for GD, its therapeutic effect may be associated with the down regulation of serum TPOAb,TGAb levels, the detection of serum TPOAb,TGAb level can be taken as one of the indicators to evaluate the clinical effect.

关 键 词：甲状腺过氧化物酶抗体 甲状腺球蛋白抗体 GRAVES病 疗效评价 

分 类 号：R977[医药卫生—药品]